1. Heart rate variability-based prediction of early cardiotoxicity in breast-cancer patients treated with anthracyclines and trastuzumab
- Author
-
Santiago Luna-Alcala, Adrián Espejel-Guzmán, Claudia Lerma, Paula Leon, Enrique C. Guerra, Jose Rodrigo Espinosa Fernández, Pavel Martinez-Dominguez, Javier Serrano-Roman, Aldo Cabello-Ganem, Alexis D. Aparicio-Ortiz, Candace Keirns, Abel Lerma, Maria Jose Santa Ana-Bayona, and Nilda Espinola-Zavaleta
- Subjects
Heart rate variability ,Breast cancer ,Anthracyclines ,Trastuzumab ,Sympathetic ,Parasympathetic ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Cardiotoxicity is a recognized complication in breast cancer (BC) patients undergoing chemotherapy with anthracyclines with or without trastuzumab. However, the prognostic value of heart rate variability (HRV) indexes for early cardiotoxicity development remains unknown. Methods Fifty BC patients underwent TTE assessment before and three months after chemotherapy. HRV indexes were obtained from continuous electrocardiograms in supine position with spontaneous breathing, active standing, and supine position with controlled breathing. The magnitude of change (Δ) between supine-standing and supine-controlled breathing was calculated. Variables were compared using t-test or ANOVA. Cardiotoxicity predictive value was assessed by ROC curve analysis. A p value of
- Published
- 2024
- Full Text
- View/download PDF